A novel virulent Litunavirus phage possesses therapeutic value against multidrug resistant Pseudomonas aeruginosa
Issued Date
2022-12-01
Resource Type
eISSN
20452322
Scopus ID
2-s2.0-85143557761
Pubmed ID
36476652
Journal Title
Scientific Reports
Volume
12
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Scientific Reports Vol.12 No.1 (2022)
Suggested Citation
Lerdsittikul V., Thongdee M., Chaiwattanarungruengpaisan S., Atithep T., Apiratwarrasakul S., Withatanung P., Clokie M.R.J., Korbsrisate S. A novel virulent Litunavirus phage possesses therapeutic value against multidrug resistant Pseudomonas aeruginosa. Scientific Reports Vol.12 No.1 (2022). doi:10.1038/s41598-022-25576-6 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/86371
Title
A novel virulent Litunavirus phage possesses therapeutic value against multidrug resistant Pseudomonas aeruginosa
Other Contributor(s)
Abstract
Pseudomonas aeruginosa is a notable nosocomial pathogen that can cause severe infections in humans and animals. The emergence of multidrug resistant (MDR) P. aeruginosa has motivated the development of phages to treat the infections. In this study, a novel Pseudomonas phage, vB_PaeS_VL1 (VL1), was isolated from urban sewage. Phylogenetic analyses revealed that VL1 is a novel species in the genus Litunavirus of subfamily Migulavirinae. The VL1 is a virulent phage as no genes encoding lysogeny, toxins or antibiotic resistance were identified. The therapeutic potential of phage VL1 was investigated and revealed that approximately 56% (34/60 strains) of MDR P. aeruginosa strains, isolated from companion animal diseases, could be lysed by VL1. In contrast, VL1 did not lyse other Gram-negative and Gram-positive bacteria suggesting its specificity of infection. Phage VL1 demonstrated high efficiency to reduce bacterial load (~ 6 log cell number reduction) and ~ 75% reduction of biofilm in pre-formed biofilms of MDR P. aeruginosa. The result of two of the three MDR P. aeruginosa infected Galleria mellonella larvae showed that VL1 could significantly increase the survival rate of infected larvae. Taken together, phage VL1 has genetic and biological properties that make it a potential candidate for phage therapy against P. aeruginosa infections.